ライフサイエンスコーパス: cyclosporine

1 JW47, using a quinolinium cation tethered to cyclosporine.

2 Interventions: Short course (3-7 days) of cyclosporine.

3 en and the less-intensive regimen) than with cyclosporine.

4 with reduced cellular toxicity compared with cyclosporine.

5 ith high-dose prednisolone, methotrexate and cyclosporine.

6 including cyclophosphamide, vincristine, and cyclosporine.

7 centiles, and history of using prednisone or cyclosporine.

8 ot genotype 1b, had increased sensitivity to cyclosporine.

9 everted by both treatment with dupilumab and cyclosporine.

10 ding cyclophilin A, a druggable target using cyclosporine.

11 osphatase calcineurin, an action shared with cyclosporine.

12 reports with definite evidence (quinine, 34; cyclosporine, 15; tacrolimus, 12).

13 al dexamethasone 40 mg for days 1 to 4, oral cyclosporine 2.5 to 3 mg/kg daily for day 1 to 28, and i

14 Topical liposomal formulation of cyclosporine, 2.0% w/w, is effective in treatment of lim

15 s received an intravenous bolus injection of cyclosporine, 2.5 mg/kg, at the onset of advanced cardio

16 isted of mycophenolate mofetil (28 days) and cyclosporine (35 days).

17 ere included in intention-to-treat analysis (cyclosporine, 400; control, 394).

18 Cyclosporine (66.4%), methotrexate (47.3%), azathioprine

19 gher in recipients aged >44 years and taking cyclosporine A (adjusted hazard ratio = 1.44; P = 0.011)

20 ipients (RTX) receiving tacrolimus (n=34) or cyclosporine A (CsA) (n=24) or an mTORi (n=26).

21 monly prescribed topical treatments included cyclosporine A (CSA) 0.05 % (71/104, 68 %), fluoromethol

22 antly, a pharmacological inhibition of CN by cyclosporine A (CsA) ameliorated the alpha-syn-induced l

23 whereas inhibitors of immunophilins, such as cyclosporine A (CsA) and FK506, inhibited CrkII, but not

24 te mofetil (MMF) or Everolimus combined with cyclosporine A (CsA) and steroids.

25 on of rituximab to corticosteroids (CSs) and cyclosporine A (CsA) as first-line therapy for newly dia

26 f an investigational therapy for severe VKC, cyclosporine A (CsA) cationic emulsion (CE), an oil-in-w

27 s are administered the calcineurin inhibitor cyclosporine A (CsA) chronically and demonstrate an incr

28 Here we show that AS and cyclosporine A (CsA) exerted synergistic inhibitory effe

29 y, and we evaluated their ability to deliver cyclosporine A (CsA) for immunomodulatory applications.

30 Whether cyclosporine A (CsA) has beneficial effects in reperfuse

31 Cyclosporine A (CsA) increases beta-catenin messenger RN

32 Cyclosporine A (CsA) is a well-known immunosuppressive a

33 Cyclosporine A (CsA) is an immunosuppressive drug which

34 Cyclosporine A (CsA) is used for the treatment of psoria

35 mic or pharmacological postconditioning with cyclosporine A (CsA) might protect the kidney from letha

36 Patients with acute GvHD are treated with cyclosporine A (CsA) or tacrolimus (FK506), which not on

37 The peptidyl-prolyl isomerase inhibitor Cyclosporine A (CsA) selectively kills EGFR+ or HER2+ br

38 after renal transplantation) conversion from cyclosporine A (CsA) to everolimus versus continued CsA

39 the RNA-induced silencing complex (RISC) of cyclosporine A (CsA) treated and control human proximal

40 Cyclosporine A (CsA), a mitochondrial permeability trans

41 The PLGA-GA NS loaded with cyclosporine A (CsA), a model peptide, upon peroral dosi

42 terestingly, the calcineurin inhibitor (CNI) cyclosporine A (CsA), an immunosuppressant used to preve

43 more than that of M6G (80.31 +/- 21.75 muM); Cyclosporine A (CsA), an inhibitor of OATP2B1, can inhib

44 ly treated with mycophenolate mofetil (MMF), cyclosporine A (CsA), and prednisone (pred).

45 f timing and duration of cardiac exposure to cyclosporine A (CsA), another putative mitochondrial pro

46 ugs, such as mycophenolate mofetil (MMF) and cyclosporine A (CsA), are often used together after HSCT

47 y side effect of the immunosuppressive drug, cyclosporine A (CsA), can be a major issue in transplant

48 in mice treated with a potent SC activator, cyclosporine A (CSA), which inhibits the phosphatase cal

49 oxidase 2 (Nox2) plays an important role in cyclosporine A (CsA)-induced chronic hypoxia.

50 s of fibrosis-related IL-6-type cytokines in cyclosporine A (CsA)-induced gingival overgrowth (GO).

51 mavirus 1 (MmuPV1) infection caused cSCCs in cyclosporine A (CsA)-treated mice, even in the absence o

52 cans without and with ABCB1 inhibition using cyclosporine A (CsA).

53 Recipients were immunosuppressed either with cyclosporine A (CsA, 1.5 mg/kg/day subcutaneously) or wi

54 Tacrolimus (Tac) and Cyclosporine A (CyA) calcineurin inhibitors (CNIs) are 2

55 from four AD patients who had received oral cyclosporine A (CyA) treatment for up to 17 months regar

56 Case 1 and 2 were treated with Cyclosporine A (CyA), case 3 was treated with Duplimab w

57 5% CI, 1.2-3.98), and immunosuppression with cyclosporine A (HR, 1.93; 95% CI, 1.14-3.3).

58 The mean doses of cyclosporine A (mg/kg/day) were recorded.

59 ium opens the channel, which is inhibited by cyclosporine A and ATP/ADP.

60 Calcineurin inhibitors such as cyclosporine A and FK506 are effective immunosuppressant

61 A-matched related donor and prophylaxis with cyclosporine A and methotrexate were associated with low

62 Recipients were injected daily with 5 mg/kg cyclosporine A and received either 10 mg/kg prednisolone

63 The immunosuppressive natural products cyclosporine A and sanglifehrin A inhibit the enzymatic

64 Cyclosporine A and tacrolimus significantly reduced IFNg

65 n was strongly potentiated by combination of cyclosporine A and UVA treatment.

66 bunit ring and unhooks it from cyclophilin D/cyclosporine A binding sites in the ATP synthase F1, pro

67 Seven received cyclosporine A for 28 days and 14 received rapamycin.

68 Rats received reduced dose cyclosporine A for 28 or 56 days to allow chronic reject

69 mus, KT recipients aged <=44 years receiving cyclosporine A had a higher risk of graft loss (adjusted

70 Protocol I showed, the VBP-allo with cyclosporine A immunosuppression was electrophysiologica

71 no reconstruction, VBP-allo with and without cyclosporine A immunosuppression, VBP autotransplantatio

72 Partial blocking of AIF release by cyclosporine A in OmpU-treated cells further suggests th

73 ucted from June 22, 2010, to March 13, 2013 (Cyclosporine A in Out-of-Hospital Cardiac Arrest Resusci

74 In the CYCLE (CYCLosporinE A in Reperfused Acute Myocardial Infarction

75 this occurs independently of cyclophilin D (cyclosporine A insensitive) rather it is through decreas

76 125 and cyclosporine A) and differentiation (cyclosporine A only) of osteoclast precursors.

77 ural Terminology codes and prescriptions for cyclosporine A ophthalmic emulsion were used to identify

78 aling pathway in lymphoma cells, either with cyclosporine A or anti-CD1d blocking antibody, prolonged

79 indicated that inhibition of calcineurin by cyclosporine A or knockdown of NFATc4 using small interf

80 Cyclosporine A selectively ameliorated the Anesthesia/Su

81 Cyclosporine A stabilizes Ets-2 mRNA and protein when th

82 keratin 16 (K16) mRNA] at baseline and after cyclosporine A treatment in 25 moderate to severe AD pat

83 Cyclosporine A treatment reduced renal expression and se

84 idized to total glutathione ratio induced by cyclosporine A treatment.

85 Cyclosporine A was used to enhance levels of the PET rad

86 ender, cardiovascular disease before LT, and cyclosporine A were associated with the risk of long-ter

87 HLA mismatches and cyclosporine A were independently associated with increa

88 -principle, the known binding interaction of Cyclosporine A with cyclophilin A protein in a yeast cel

89 sporivir, a nonimmunosuppressive analogue of cyclosporine A with potent cyclophilin inhibition proper

90 -dependent migration (including SP600125 and cyclosporine A) and differentiation (cyclosporine A only

91 neuronal co-cultures through the addition of cyclosporine A, a potent immune-modulator.

92 ubating cells with the cyclophilin inhibitor cyclosporine A, a treatment that triggered efficient ER

93 Cyclosporine A, an inhibitor of mitochondria permeabilit

94 rapies using calcineurin inhibitors, such as cyclosporine A, are associated with a higher incidence o

95 N-acetyl-L-cysteine and cyclosporine A, blocked ethanol and acetaldehyde-induced

96 tide) and a model hydrophobic macromolecule (Cyclosporine A, CsA), herein we provide a mechanistic un

97 Ca(2+) signaling or calcineurin with BAPTA, cyclosporine A, or FK506 prevented activation of NF-kapp

98 tochondrial Ca(2+) influx, by mPTP inhibitor cyclosporine A, sanglifehrin, and in cyclophilin D knock

99 Upon introducing the nephrotoxin, Cyclosporine A, the epithelial barrier is disrupted in a

100 Cyclosporine A, with or without concurrent corticosteroi

101 rtrophy group (n = 5), and aortic-banded and cyclosporine A- treated cardiomyopathy group (n = 5).

102 Cyclosporine A-induced nephrotoxicity is multifactorial

103 CMV reactivation occurred earlier in cyclosporine A-treated animals compared with those recei

104 able and orally bioavailable natural product cyclosporine A.

105 imilar concentration as pharmaceutical grade cyclosporine A.

106 s a target of the natural products FK506 and Cyclosporine A.

107 e cellular receptor of the immunosuppressant cyclosporine A.

108 e trough level (C0) and used higher doses of cyclosporine A.

109 transplantation (HCT) and a 45-day course of cyclosporine A.

110 e trough level (C0) and used higher doses of cyclosporine A.

111 decreased sensitivity to the Rgg2 antagonist cyclosporine A.

112 pulses of cyclophosphamide, vincristine, or cyclosporine A; or salvage splenectomy are considered.

113 tion were observed both in mice treated with cyclosporine, a known stimulator of the HCM response, an

114 y higher than that of the standard inhibitor cyclosporine-A (CsA).

115 Administration of cyclosporine-A to enhance graft survival demonstrated th

116 2 expression in HGFs, whereas treatment with cyclosporine-A, which inhibited CD147 expression, reduce

117 tion of the Itpr2 promoter was attenuated by cyclosporine-A.

118 had been prescribed psoralen, methotrexate, cyclosporine, acitretin, adalimumab, etanercept, inflixi

119 onary artery to receive a bolus injection of cyclosporine (administered intravenously at a dose of 2.

120 Short-term cyclosporine administration in mice augmented the abunda

121 Cyclosporine administration rapidly normalized the abund

122 The cyclosporine-analog alisporivir has recently been shown

123 stress, but did show increased resistance to cyclosporine and a TS phenotype.

124 received cyclophosphamide at 120 mg/kg plus cyclosporine and antibacterial, antiviral, and antifunga

125 role for ultraviolet radiation exposure, and cyclosporine and azathioprine may contribute as photosen

126 come at discharge was comparable between the cyclosporine and control groups: 7 (1.8%) vs 5 (1.3%) pa

127 plified biphasic (emulsion) system employing cyclosporine and difluprednate as model drugs.

128 Cyclosporine and difluprednate emulsions were chosen as

129 diffusion from oil to aqueous phase for both cyclosporine and difluprednate emulsions.

130 Cyclosporine and lifitegrast, the 2 US Food and Drug Adm

131 sus-host disease prophylaxis was composed of cyclosporine and methotrexate.

132 ute GVHD compared with patients treated with cyclosporine and mycophenolate mofetil alone.

133 efficacy of adding sirolimus to the standard cyclosporine and mycophenolate mofetil prophylaxis thera

134 In conclusion, the addition of sirolimus to cyclosporine and mycophenolate mofetil resulted in a low

135 Adding sirolimus to cyclosporine and mycophenolate mofetil resulted in a sig

136 ither the standard GVHD prophylaxis regimen (cyclosporine and mycophenolate mofetil) or the triple-dr

137 d intensity conditioning to PBSC h-HSCT with cyclosporine and mycophenolate mofetyl + PTCY (n = 32) o

138 HCV replicons, containing or lacking NS2, to cyclosporine and other direct-acting antiviral agents.

139 d for effects on conidiation, hyphal growth, cyclosporine and stress resistance, and insect virulence

140 osuppressed either with cyclosporine or with cyclosporine and sunitinib.

141 We confirm that the immunosuppressive drugs cyclosporine and tacrolimus also inhibit BCR-mediated ly

142 Immunosuppressant drugs such as cyclosporine and tacrolimus but not rapamycin also inhib

143 and to assess potential differences between cyclosporine and tacrolimus.

144 iple comorbidities, concomitant therapy with cyclosporine, and a high Psoriasis Area and Severity Ind

145 ch as penicillin, immunosuppressants such as cyclosporine, and cytostatics such as bleomycin.

146 raacetate-AM acetoxymethyl ester (BAPTA-AM), cyclosporine, and inhibitor of nuclear factor of activat

147 rferon (IFN-alpha), telaprevir, daclatasvir, cyclosporine, and ribavirin, despite no prior exposure t

148 onal agents such as methotrexate, acitretin, cyclosporine, and the advanced small molecule apremilast

149 inary metabolic patterns varied over time in cyclosporine- and tacrolimus-treated patients and were s

150 Compared with anti-TNF-alpha and cyclosporine, anti-IL-12/23 treatment resulted in a grea

151 Mixed-chirality peptide macrocycles such as cyclosporine are among the most potent therapeutics iden

152 orticosteroids; other medications, including cyclosporine, are used in patients who fail to respond.

153 n inhibitors, such as tacrolimus (FK506) and cyclosporine, are widely used as standard immunosuppress

154 CypA antagonists, such as cyclosporines, are potent inhibitors of HCV replication.

155 Objective: To assess a short course of cyclosporine as first-line therapy for DIHS.

156 with an immunosuppressive regimen including cyclosporine, azathioprine, and prednisolone.

157 ant, and was higher in recipients prescribed cyclosporine/azathioprine maintenance therapy (aIRR 1.79

158 belatacept less-intensive-based (n = 71), or cyclosporine-based (n = 73) immunosuppression.

159 has been demonstrated to be as efficient as cyclosporine-based immunosuppression and is associated w

160 pt-based immunosuppression, as compared with cyclosporine-based immunosuppression, was associated wit

161 domized to cyclosporine continued to receive cyclosporine-based immunosuppression.

162 The cyclosporine-based regimen was associated with FMI decre

163 The cyclosporine-based regimen was independently associated

164 Compared with cyclosporine, belatacept was associated with improved HR

165 Cyclosporine blocked de novo formation of the membranous

166 7-11 posttransplant or (2) standard-exposure cyclosporine, both with mycophenolate mofetil and cortic

167 anti-retroviral activity that is reversed by cyclosporine, but it does not activate Nf-kappaB or AP-1

168 pt) by 106 (27.2%), acitretin by 57 (14.6%), cyclosporine by 30 (7.7%), fumaric acid esters by 19 (4.

169 n, nonsteroidal anti-inflammatory drugs, and cyclosporine, can be effective for both skin and systemi

170 Patients initially randomized to cyclosporine continued to receive cyclosporine-based imm

171 none of the sites treated with conventional cyclosporine cream or placebo gel.

172 cyclosporine lipogel, 2.0%, or conventional cyclosporine cream, 2.0% w/w.

173 uced blocks in THP-1 cells by treatment with cyclosporine (Cs) or its nonimmunosuppressive analogue S

174 kidney-pancreas transplant recipients during cyclosporine (CSA) and TAC eras, analyzed by intention-t

175 o application of P2Ns was demonstrated using cyclosporine (CsA) as a model peptide.

176 stagraf XL) qd, tacrolimus (Prograf) bid, or cyclosporine (CsA) bid.

177 HIV, tacrolimus (TAC) trough levels (C0) or cyclosporine (CsA) drawn at C0 or 2 hours after dosing (

178 Cyclosporine (CsA) is an immunosuppressant that is highl

179 Tacrolimus (Tac) and Cyclosporine (CsA) levels obtained during the first 15 d

180 We recently utilized the cyclosporine (CsA) washout assay, in which TRIM-CypA-med

181 HIV-1 capsid stability were assessed using a cyclosporine (CsA) washout assay.

182 ing as defined in parallel drug addition and cyclosporine (CsA) washout assays to detect the kinetics

183 ted in both virus strains in the presence of cyclosporine (CsA), indicating that N57A infectivity is

184 locked by the nonimmunosuppressive analog of cyclosporine (CsA), sarcosine-3(4-methylbenzoate)-CsA (S

185 Groups included: no treatment, full dose cyclosporine (CsA, 10 mg/kg per day), ixazomib (0.25 mg/

186 ate the efficacy of sirolimus in addition to cyclosporine (CSP) and mycophenolate mofetil (MMF) for g

187 Cyclosporine did not reduce the incidence of the separat

188 d been referred for primary PCI, intravenous cyclosporine did not result in better clinical outcomes

189 with nonshockable cardiac rhythm after OHCA, cyclosporine does not prevent early multiple organ failu

190 d their efficacy in combination with reduced cyclosporine dosing in de novo heart transplant recipien

191 itraconazole, voriconazole, or posaconazole; cyclosporine; erythromycin or clarithromycin; dronedaron

192 ate analyses, the use of Olopatadine 0.1% or cyclosporine eye drops before DALK (OR = 14.51, 95% CI =

193 of Olopatadine 0.1% or any concentration of cyclosporine eye drops prior to DALK.

194 ed (1) everolimus with reduced-exposure CNI (cyclosporine) followed by CNI withdrawal at week 7-11 po

195 y therefore be noninferior to treatment with cyclosporine for inducing and maintaining a complete or

196 , laser and light-based therapy, and topical cyclosporine for ocular rosacea.

197 of cyclophilins, including the approved drug cyclosporine, greatly reduced the viability of glioblast

198 n the rituximab group and in 20 (31%) in the cyclosporine group (P = 0.06).

199 A total of 395 patients in the cyclosporine group and 396 in the placebo group received

200 rate of the primary outcome was 59.0% in the cyclosporine group and 58.1% in the control group (odds

201 R]) ages were 63.0 (54.0-71.8) years for the cyclosporine group and 66.0 (57.0-74.0) years for the co

202 ) in the rituximab group and 13 (20%) in the cyclosporine group had a complete or partial remission (

203 he rituximab group and 34 of 65 (52%) in the cyclosporine group had a complete or partial remission (

204 set of advanced cardiovascular life support (cyclosporine group) or no additional intervention (contr

205 duration in the rituximab group than in the cyclosporine group.

206 , respectively (belatacept more-intensive vs cyclosporine: hazard ratio [HR] = 0.95; 95% confidence i

207 13.9%, respectively (belatacept 4-weekly vs cyclosporine: HR = 1.06, 95% CI 0.35-3.17, P = .92; bela

208 -1.92; P = .89; belatacept less-intensive vs cyclosporine: HR = 1.61; 95% CI 0.85-3.05; P = .15).

209 I 0.35-3.17, P = .92; belatacept 8-weekly vs cyclosporine: HR = 2.00, 95% CI 0.75-5.35, P = .17).

210 s, approximately 35x10(6)) versus vehicle in cyclosporine-immunosuppressed swine with a chronic left

211 nous steroid therapy in 35 patients (26.5%), cyclosporine in 98 patients (74.2%), and azathioprine in

212 Rituximab was noninferior to cyclosporine in inducing complete or partial remission o

213 ture clinical trials should assess liposomal cyclosporine in larger study populations.

214 Short courses of cyclosporine in the acute care setting may be an alterna

215 The pharmacokinetics of cyclosporine in the setting of vismodegib administration

216 Attempts to use topical cyclosporine in treatment of psoriasis have failed becau

217 ho-NKCC2, and treatment of isolated TAL with cyclosporine increased the chloride affinity and transpo

218 ble to OPC, and blockade of TCR signaling by cyclosporine induced susceptibility.

219 tates exploration into the role of miRNAs in cyclosporine-induced nephrotoxicity (CIN) and the gene p

220 pendent studies have convincingly shown that cyclosporine inhibit replication of several different co

221 the rate and extent of drug distribution of cyclosporine into the aqueous phase, probably by suppres

222 Cyclosporine is generally allowed in lactating women, al

223 for concurrent use of verapamil; diltiazem; cyclosporine; ketoconazole, itraconazole, voriconazole,

224 Cyclosporine led to a more pronounced global transcripto

225 pid status, body mass index (BMI), and blood cyclosporine levels (C0 and C2) were determined.

226 egib administration and weekly monitoring of cyclosporine levels ensured that therapeutic immunosuppr

227 %) in DSS was seen in all sites treated with cyclosporine lipogel, (P < .001; 95% CI, 77.48-88.22).

228 ird arm comprised 7 patients randomized with cyclosporine lipogel, 2.0% or standard clobetasol propio

229 was observed after 2 weeks of treatment with cyclosporine lipogel, 2.0% w/w (P < .001; 95% CI, 13.77-

230 4 patients were randomized to receive either cyclosporine lipogel, 2.0% weight by weight (w/w), or pl

231 d arm, 7 patients were randomized to receive cyclosporine lipogel, 2.0%, or conventional cyclosporine

232 (41%) psoriasis lesional sites treated with cyclosporine lipogel, 85.7% of sites treated with clobet

233 rimental and clinical evidence suggests that cyclosporine may attenuate reperfusion injury and reduce

234 was not significantly different between the cyclosporine (median, 10.0; IQR, 7.0-13.0) and the contr

235 between 1989 and 2015, prescribed any ISDs (cyclosporine, methotrexate, azathioprine, anti-TNF drugs

236 Based on these results, the combination of cyclosporine, mycophenolate mofetil, and sirolimus has b

237 til) or the triple-drug combination regimen (cyclosporine, mycophenolate mofetil, and sirolimus).

238 GVHD prophylaxis comprised cyclosporine, mycophenolate mofetil, and sirolimus.

239 macokinetic interaction was observed between cyclosporine, mycophenolic acid, and RAL.

240 eks of systemic treatment (dupilumab n = 21, cyclosporine n = 8) were analyzed.

241 of systemic treatment (dupilumab [n = 22] or cyclosporine [n = 8]) and from 31 healthy controls were

242 rial only); and (c) impact of belatacept and cyclosporine on side effect experience and HRQoL.

243 attributable mostly to a single medication, cyclosporine ophthalmic emulsion (Restasis, Allergan, Ir

244 odes indicative of DED and prescriptions for cyclosporine ophthalmic emulsion identified a DED popula

245 r samples from patients treated with topical cyclosporine or corticosteroids showed a dramatic reduct

246 as 2-fold greater than the mean duration for cyclosporine or fumaric acid esters.

247 astatin, whereas combining atorvastatin with cyclosporine or mycophenolate in place of rapamycin was

248 in 4.5 mg/kg plus standard GVHD prophylaxis (cyclosporine or tacrolimus plus methotrexate or mycophen

249 Allografts were immunosuppressed either with cyclosporine or with cyclosporine and sunitinib.

250 data on combining biologics with acitretin, cyclosporine, or a second biologic.

251 orticosteroids, intravenous immunoglobulins, cyclosporine, plasmapheresis, thalidomide, cyclophospham

252 Experimental evidence suggests that cyclosporine prevents postcardiac arrest syndrome by att

253 igher risk of PBC recurrence, whereas use of cyclosporine reduced risk of PBC recurrence (HR, 0.62; 9

254 ive belatacept regimens as compared with the cyclosporine regimen (hazard ratio with the more-intensi

255 regimen, and 131 of the 215 treated with the cyclosporine regimen were followed for the full 84-month

256 th belatacept regimens but declined with the cyclosporine regimen.

257 n, a less-intensive belatacept regimen, or a cyclosporine regimen.

258 This block was prevented by cyclosporine resistance mutations in NS5A.

259 and differential effects on conidiation and cyclosporine resistance.

260 re-intensive, belatacept less-intensive, and cyclosporine, respectively (belatacept more-intensive vs

261 A 7-day course of cyclosporine resulted in clinical resolution of the DIHS

262 A 3-day course of cyclosporine resulted in rapid and sustained clinical im

263 rsensitivity reaction that were treated with cyclosporine, resulting in rapid and significant clinica

264 ate (RR, 0.98 [95% CI, 0.78-1.23]; P = .83), cyclosporine (RR, 1.16 [95% CI, 0.48-2.80]; P = .49), an

265 Moreover, the lack of effect of cyclosporine rules out the canonical signaling pathway i

266 th and purified recombinant BbCypA displayed cyclosporine sensitive PPIase activity.

267 d by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel.

268 s 3 and 4 after transplantation, followed by cyclosporine starting on day 5.

269 months in case of partial response) or oral cyclosporine (starting at a dose of 3.5 mg per kilogram

270 rred, new observational studies suggest that cyclosporine, tacrolimus, and rituximab may be effective

271 rapies, including thiopurines, methotrexate, cyclosporine, tacrolimus, TNF-alpha antagonists, vedoliz

272 is approach was validated for phylloquinone, cyclosporine, testosterone undecanoate, cabazitaxel and

273 s to be a safe option for patients receiving cyclosporine therapy with routine monitoring.

274 and BKVAN, human leukocyte antigen mismatch, cyclosporine therapy, and indication biopsy for dysfunct

275 uppressed heart transplant patient receiving cyclosporine therapy.

276 Diffusion of cyclosporine to aqueous phase exhibited a decreasing tre

277 unosuppressive drugs (corticosteroids and/or cyclosporine) to reduce inflammation followed by the add

278 was found to decrease the rate and extent of cyclosporine transfer from oil to aqueous phase but had

279 reported better absolute PCSs compared with cyclosporine-treated patients.

280 s factor-a (TNF-alpha; etanercept, n=50), or cyclosporine treatment (n=50).

281 ined to determine the timing and efficacy of cyclosporine treatment.

282 ardial function than TNF-alpha inhibition or cyclosporine treatment.

283 , higher serum level of uric acid, and blood cyclosporine trough level (C0) and used higher doses of

284 , higher serum level of uric acid, and blood cyclosporine trough level (C0) and used higher doses of

285 nine, BUN, folate and vitamin B12, and blood cyclosporine trough level (C0) are independently associa

286 tinine (P=0.03), and BUN (P=0.05), and blood cyclosporine trough level (C0, P=0.005) were independent

287 Short-term cyclosporine use has been combined with etanercept or ad

288 gnificantly different between the 98 (24.5%) cyclosporine vs 101 (25.6%) control patients at hospital

289 In both study groups, 5.0 mg/kg of cyclosporine was administered orally twice daily startin

290 Despite the low patient size, cyclosporine was associated with a promising significant

291 .337-0.891; p = 0.015), while treatment with cyclosporine was associated with increased risk of death

292 Cyclosporine was combined with azathioprine or mycopheno

293 Conclusions and Relevance: A short course of cyclosporine was of therapeutic benefit in the treatment

294 Cyclosporine was preferred for diabetic, hepatitis C-inf

295 elatacept 4-weekly, belatacept 8-weekly, and cyclosporine were 11.1%, 21.9%, and 13.9%, respectively

296 elatacept 4-weekly, belatacept 8-weekly, and cyclosporine were 67.0, 68.7, and 42.7 mL/min per 1.73 m

297 l, had limitations, glucocorticosteroids and cyclosporine were the most promising systemic immunomodu

298 eview the putative link between COVID-19 and cyclosporine, while we await more robust clinical data.

299 t transplant, immunosuppressed with low-dose cyclosporine, who presented to a specialty dermatology t

300 We aimed to test whether cyclosporine would improve clinical outcomes and prevent